Based on similar medications, retatrutide probably won't be recommended for: People with a personal or family history of medullary thyroid cancer Those with multiple endocrine neoplasia syndrome type 2 Anyone with a history of pancreatitis Pregnant or breastfeeding women Children and adolescents (under 18) People with severe kidney or liver disease Now, what about people without diabetes who want to lose weight
Obesity treatment follows similar logic
GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone produced in the gastrointestinal tract in response to food intake
So the major reason why your bathtub overflows is because the faucet is still pouring water into it and the major reason why you have high blood sugar and diabetes is because your liver is still secreting, it's doing de novo on glucogenesis, it's creating sugar and dumping the blood treatment is not to post it
The combination is now advancing into Phase 3 trials , expected to complete by 20262027
In the case of Wegovy, overweight or obese patients with preexisting cardiovascular disease who are prescribed the drug to prevent the risk of heart attacks or strokes may get Medicare coverage